Mimotopes and Genzyme Pharmaceuticals to collaborate
27 January, 2006 by Ruth BeranPharmAust's (ASX:PAA) subsidiary Mimotopes and US-based Genzyme Corporation have signed a strategic alliance agreement to provide a total suite of peptide products and services to both companies' customer bases.
PolyNovo in $11m deal with Medtronic
25 January, 2006 by Helen SchullerPolyNovo Biomaterials, jointly owned by CSIRO and Xceed Biotechnology (ASX:XBL) has signed a partnering and licensing agreement potentially worth more than AUD$11 million with giant US-based device maker Medtronic.
Epitan opts for name change
25 January, 2006 by Ruth BeranMelbourne-based Epitan (ASX:EPT) is planning to change its name to Clinuvel Pharmaceuticals.
New Peptech CEO excited by Australian opportunities
25 January, 2006 by Graeme O'NeillJohn Chiplin, the new CEO of Sydney biopharma Peptech (ASX:PTD), sees strong similarities between the state of Australia's biotechnology industry and California's nascent biotechnology industry in San Diego in the mid-1980s.
BioProspect raises $1.2m
24 January, 2006 by Ruth BeranNatural pesticide developer BioProspect (ASX:BPO) has raised AUD$1.2 million from its fully underwritten rights offer, where shareholders could subscribe for one new share, at a price of $0.02, and a free attaching option for every three shares held.
CathRx pleased by positive catheter trial results
24 January, 2006 by Ruth BeranA clinical trial conducted by Sydney medical device company CathRx (ASX:CXD) has shown that its catheters can appropriately diagnose arrythmias when measuring electrical signals generated by the heart.
Phosphagenics initiates anti-cancer compound animal trials
24 January, 2006 by Helen SchullerMelbourne's Phosphagenics (ASX:POH, AIM:PSG) will commence animal studies later this month on its patented anti-cancer compound.
Metabolic CEO keen to prove worth of lead drugs
24 January, 2006 by Graeme O'NeillMetabolic Pharmaceuticals (ASX:MBP) CEO Dr Roland Scollay is feeling no pain as his Melbourne-based biopharmaceutical company heads into a potentially momentous year in the clinic for its two lead compounds, the anti-obesity drug AOD9604 and chronic neuropathic pain lead ACV1.
Narhex boss sets out path to market
24 January, 2006 by Helen SchullerSydney-based Narhex has begun recruiting for an early-stage trial of an HIV drug. Helen Schuller spoke with the company's MD, John Mills, about HIV drug development, working in China, and good management.
Medical device industry pioneer Paul Trainor dies
23 January, 2006 by Michael HirshornPaul Trainor AO, 78, 'father of Australia's medical device industry' died on January 13, 2006.
Phylogica to collaborate with Canadian biotech
20 January, 2006 by Helen SchullerPerth-based Phylogica (ASX:PYC) has entered into an international collaboration agreement with Canadian biotechnology company Axela Biosensors to fast track the discovery new drug candidates for inflammatory disease.
Burrill expects good year for biotech
20 January, 2006 by Ruth BeranThe year 2006 will be a good one for biotech, according to San Francisco's bullish biotech maven, Steve Burrill.
Govts should stay out of agbiotech business: Raff
20 January, 2006 by Graeme O'NeillGovernment involvement in agricultural biotech industries is stifling innovation, a leading industry figure has warned.
Anadis hopes to extend Travelan uses
20 January, 2006 by Helen SchullerMelbourne biopharma Anadis (ASX:ANX) is investigating the use of its over-the-counter traveller's diarrhoea product, Travelan, for additional gastrointestinal therapeutic indications.
NeuroDiscovery and CSIRO sign collaboration agreement
19 January, 2006 by Helen SchullerPerth-based neurology-focused biotech company NeuroDiscovery (ASX:NDL) and the CSIRO have entered into a research collaboration agreement.
